Mark E.T. Penfold

5.2k citations

31 papers · 4.2k indexed · 2 hit papers · h-index 24

Impact in

Immunology top 1%
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- interferon and immune responses
- Immune Cell Function and Interaction
Oncology top 1%
- Chemokine receptors and signaling

Papers in

Immunology 20
- Immunotherapy and Immune Responses 9
- interferon and immune responses 5
- Immune Cell Function and Interaction 4
Virology 3
- HIV Research and Treatment 2

Co-authors: Thomas J. SchallYu WangZhenhua Miao Edward S. Mocarski Anthony L. Cunningham K Wright Dan R. Littman Calvin J. Kuo
Journals: Journal of Virology (4 papers)Virology (3 papers)PLoS ONE (2 papers)Proceedings of the National Academy of Sciences (2 papers)The Journal of Immunology (2 papers)
Partner nations: United States Australia Germany

In The Last Decade

Mark E.T. Penfold

31 papers receiving 4.1k citations

Hit Papers

align trajectories log scale

Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis 2013 · 482 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Nature
2006 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Mark E.T. Penfold

Since Specialization

Citations

This map shows the geographic impact of Mark E.T. Penfold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E.T. Penfold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E.T. Penfold more than expected).

Fields of papers citing papers by Mark E.T. Penfold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E.T. Penfold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E.T. Penfold. The network helps show where Mark E.T. Penfold may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark E.T. Penfold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E.T. Penfold Line = papers co-authored together Mark E.T. Penfold links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Babington Academy in Leicester Intercultural Education ·Mark E.T. Penfold	2018	1
2	Chemerin Connects Fat to Arterial Contraction Arteriosclerosis Thrombosis and Vascular Biology ·Stephanie W. Watts, Anne M. Dorrance, Mark E.T. Penfold, Jillian L. Rourke, Christopher J. Sinal, Bridget M. Seitz, Timothy J. Sullivan, Trevor T. Charvat, Janice Thompson, Robert Burnett, Gregory D. Fink	2013	128
3	Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis Nature ·Bi‐Sen Ding, Zhongwei Cao, Raphaël Lis, Daniel J. Nolan, Peipei Guo, Michael Simons, Mark E.T. Penfold, Koji Shido, Sina Y. Rabbany, Shahin Rafii Hit paper breakdown →	2013	482
4	Differential effects of CXCR4‐CXCL12‐ and CXCR7‐CXCL12‐mediated immune reactions on murine P0_106–125‐induced experimental autoimmune neuritis Neuropathology and Applied Neurobiology ·Anna Brunn, Olaf Utermöhlen, S. López-Pedrajas, Gennadiy Volokitin, Cortney Cronberg Barko, Tobias Blau, Maëlle Plawecki, Mark E.T. Penfold, Manuel Montesinos‐Rongen, Martina Deckert	2013	11
5	C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN Journal of the American Society of Nephrology ·Hong Xiao, Daniel J. Dairaghi, Jay P. Powers, Linda Ertl, Trageen Baumgart, Yu Wang, Lisa Seitz, Mark E.T. Penfold, Lin Gan, Peiqi Hu, Bao Lu, Norma P. Gerard, Craig Gérard, Thomas J. Schall, Juan C. Jaén, Ronald J. Falk, J. Charles Jennette	2013	257
6	Rapid Uptake and Degradation of CXCL12 Depend on CXCR7 Carboxyl-terminal Serine/Threonine Residues Journal of Biological Chemistry ·Frauke Hoffmann, Andreza Marques Campos, Dagmar Schütz, Mark E.T. Penfold, Yung Hou Wong, Stefan Schulz, Ralf Stumm	2012	78
7	CXCR7 Protein Expression in Human Adult Brain and Differentiated Neurons PLoS ONE ·Saori Shimizu, Michael P. Brown, Rajarshi Sengupta, Mark E.T. Penfold, Olimpia Meucci	2011	57
8	The Chemokine Receptor CXCR7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects Cancer Research ·Kirsten Hattermann, Janka Held‐Feindt, Ralph Lucius, Susanne Sebens Müerköster, Mark E.T. Penfold, Thomas J. Schall, Rolf Mentlein	2010	239
9	Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease Journal of Pharmacology and Experimental Therapeutics ·Matthew J. Walters, Yu Wang, Petra Halász, Trageen Baumgart, Bin Zhao, Daniel J. Dairaghi, Pirow Bekker, Linda Ertl, Mark E.T. Penfold, Juan C. Jaén, Satish Keshav, Emily Wendt, Andrew M. K. Pennell, 依藤史郎, Zheng Wei, John Joseph Wright, Thomas J. Schall	2010	130
10	The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection Kidney International ·Matthias A. Neusser, Gaëlle Daude, Heinz Regele, Clemens D. Cohen, Thomas Fehr, Dontscho Kerjaschki, Rudolf P. Wüthrich, Mark E.T. Penfold, Thomas J. Schall, Stephan Segerer	2010	34
11	Pathogenic role of CXCR7 in rheumatoid arthritis Arthritis & Rheumatism ·Kaori Watanabe, Mark E.T. Penfold, Akio Matsuda, В. Вытов, Kayoko Kaneko, Yoshishige Miyabe, Kenji Matsumoto, Thomas J. Schall, Nobuyuki Miyasaka, Toshihiro Nanki	2010	72
12	CXCR7 Protein Is Not Expressed on Human or Mouse Leukocytes The Journal of Immunology ·Robert Berahovich, Brian A. Zabel, Mark E.T. Penfold, Susanna Lewén, Yu Wang, Zhenhua Miao, Lin Gan, Jaime Ibáñez, Avdonina Lm, Igor I. Slukvin, Kathleen E. McGrath, Juan C. Jaén, Thomas J. Schall	2010	64
13	Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands The Journal of Immunology ·Brian A. Zabel, Yu Wang, Susanna Lewén, Robert Berahovich, Mark E.T. Penfold, Penglie Zhang, Jay P. Powers, 夕真有路, Zhenhua Miao, Bin Zhao, Ali Jalili, Anna Janowska‐Wieczorek, Juan C. Jaén, Thomas J. Schall	2009	245
14	CXCR7 Is Expressed in B Acute Lymphoblastic Leukemia (ALL) Cells and Mediates Their Transendothelial Migration. Blood ·Ali Jalili, Neeta Shirvaikar, Imran Mirza, K.S. Park, Mark E.T. Penfold, Thomas J. Schall, Anna Janowska‐Wieczorek	2008	1
15	Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1CCMV Virology ·H. M. Thomas, Jiqing Sai, Mark E.T. Penfold, Ann Richmond, Tim E. Sparer	2007	18
16	A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1 Virology ·Mark E.T. Penfold, Zhenhua Miao, Yu Wang, Jeanetvska Urdaneta González, Mark R. Schleiss	2003	17
17	Potent Immunosuppressive Activities of Cytomegalovirus- Encoded Interleukin-10 Journal of Virology ·Juliet V. Spencer, Kristen M. Lockridge, Peter A. Barry, Gaofeng Lin, Monica Tsang, Mark E.T. Penfold, Thomas J. Schall	2002	245
18	A review of genetic differences between limited and extensively passaged human cytomegalovirus strains Reviews in Medical Virology ·Mark N. Prichard, Mark E.T. Penfold, G M Duke, Richard R. Spaete, George Kemble	2001	148
19	Formation of Cytomegalovirus DNA Replication Compartments Defined by Localization of Viral Proteins and DNA Synthesis Virology ·Mark E.T. Penfold, Edward S. Mocarski	1997	97
20	Herpes Simplex Virus Protein Targets for CD4 and CD8 Lymphocyte Cytotoxicity in Cultured Epidermal Keratinocytes Treated with Interferon-γ The Journal of Infectious Diseases ·Zorka Mikloška, Alison Kesson, Mark E.T. Penfold, Anthony L. Cunningham	1996	75

About Mark E.T. Penfold

Mark E.T. Penfold is a scholar working on Immunology, Virology, Oncology, Epidemiology and Genetics, having authored 31 papers that have together received 4.2k indexed citations. Recurring topics across this work include Chemokine receptors and signaling (15 papers), Immunotherapy and Immune Responses (9 papers), Cytomegalovirus and herpesvirus research (9 papers), Herpesvirus Infections and Treatments (7 papers), interferon and immune responses (5 papers), Immune Cell Function and Interaction (4 papers), HIV Research and Treatment (2 papers) and Virus-based gene therapy research (2 papers). The work is most often cited by research in Immunology (2.0k citations), Oncology (1.8k citations), Epidemiology (1.3k citations), Hepatology (282 citations) and Immunology and Allergy (212 citations). Mark E.T. Penfold has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Thomas J. Schall, Yu Wang, Zhenhua Miao, Edward S. Mocarski, Anthony L. Cunningham, K Wright, Dan R. Littman, Calvin J. Kuo, Maureen Howard and Kevin Wei. Their work appears in journals such as Journal of Virology, Virology, PLoS ONE, Proceedings of the National Academy of Sciences and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact